My watch list  


Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]


  1. ^ Urbanowicz, W; Sogni, P, Moreau, R, Tazi, K A, Barriere, E, Poirel, O, Martin, A, Guimont, M C, Cazals-Hatem, D, Lebrec, D (2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut 53: 1844-1849. “publisher= BMJ Publishing Group Ltd & British Society of Gastroenterology”
  2. ^ Tezosentan does not appear to improve symptoms for patients with acute heart failure. Medical Studies/Trials. (7-Nov-2007). Retrieved on 2007-11-24.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tezosentan". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE